

From Lab to Pharmacy Shelves: The Story of a Plant Derived Anticancer Drug, "Paclitaxel"

Maira Junjua

Department of Biosciences, CIIT, Islamabad, Pakistan, maira.junjua@comsats.edu.pk

Sana Jafar

Bioresource Research Centre (BRC), Islamabad, Pakistan

Fazeelat Karamat

Department of Biosciences, CIIT, Islamabad, Pakistan

Faheem Ahmed

Department of Biosciences, CIIT, Islamabad, Pakistan

Follow this and additional works at: <https://corescholar.libraries.wright.edu/jbm>



Part of the [Biodiversity Commons](#), and the [Biology Commons](#)

Recommended Citation

Junjua, M., Jafar, S., Karamat, F., & Ahmed, F. (2015). From Lab to Pharmacy Shelves: The Story of a Plant Derived Anticancer Drug, "Paclitaxel", *Journal of Bioresource Management*, 2 (4).

DOI: 10.35691/JBM.5102.0038

ISSN: 2309-3854 online

This Article is brought to you for free and open access by CORE Scholar. It has been accepted for inclusion in *Journal of Bioresource Management* by an authorized editor of CORE Scholar. For more information, please contact library-corescholar@wright.edu.

From Lab to Pharmacy Shelves: The Story of a Plant Derived Anticancer Drug, "Paclitaxel"

© Copyrights of all the papers published in Journal of Bioresource Management are with its publisher, Center for Bioresource Research (CBR) Islamabad, Pakistan. This permits anyone to copy, redistribute, remix, transmit and adapt the work for non-commercial purposes provided the original work and source is appropriately cited. Journal of Bioresource Management does not grant you any other rights in relation to this website or the material on this website. In other words, all other rights are reserved. For the avoidance of doubt, you must not adapt, edit, change, transform, publish, republish, distribute, redistribute, broadcast, rebroadcast or show or play in public this website or the material on this website (in any form or media) without appropriately and conspicuously citing the original work and source or Journal of Bioresource Management's prior written permission.

FROM LAB TO PHARMACY SHELVES: THE STORY OF A PLANT DERIVED ANTICANCER DRUG, “PACLITAXEL”

Maira Junjua^{1*}, Sana Jafar², Fazeelat Karamat¹ Faheem Ahmed¹

¹Department of Biosciences, CIIT, Islamabad, Pakistan.

²Bioresoure Research Centre (BRC) Islamabad, Pakistan.

*Email: maira.junjua@comsats.edu.pk

ABSTRACT

Paclitaxel (Taxol[®]) is a highly praised anticancer drug, known for its efficiency in treating different cancers. It belongs to a class of compounds called taxanes that are derived from the plants of the genus *Taxus*. This drug is now FDA approved, but there was a time when the name Taxol was less known to the scientific world. Taxol, being a unique molecule in its structure, properties and mechanism of action, has undergone more than 30 years of trials, and faced a lot of hurdles to leave the bench of a laboratory and reach the shelves of a pharmacy. This review focuses on the story of Taxol, how it began and how it achieved the status of Paclitaxel.

Key words: secondary metabolites, *Taxus brevifolia*, taxol, Paclitaxel.

INTRODUCTION

Secondary metabolites of plants have always fascinated scientists due to their unique and diverse properties that could be exploited for their usefulness for mankind. These compounds are involved in plant defense systems that respond to environmental aggressors, where they serve as the molecules of communication and defense warfare. Under the attack of a predator/pathogen, they make the plants unpalatable, toxic for the attacker and also play a role as warning signals for other plants present in close proximity (Rhoades 1979, Friedman 2007, Gershezon and Keris 1999). Applications of secondary metabolites in the plant defense system against predators/pathogens provided the researchers a clue to their possible pharmacological implications in combating human diseases. These molecules constitute a highly diversified group. According to a rough estimate, almost 40,000 different secondary metabolites of plants exist in nature (Denis RA Mans, 2013). Among them, only 10,000 have been chemically characterized, while a large number still remains to be explored for pharmaceutical implications (Firm and Jones 2003; Wink 2003). This concern triggered a significant

report that was presented by the US National Institute of Cancer, in which 122 structurally different compounds were isolated from only 94 species of medicinal plants that had been used in traditional medicines in the past (Fabricant and Farnsworth 2001). In the present paper, we reviewed an important invention of cancer treatment, Taxol (commonly known as paclitaxel).

Paclitaxel (Taxol) occurs in the form of crystalline powder of white to off-white color with an empirical formula of C₁₇H₅₁NO₁₄ and is a plant derived anticancer drug that is the first drug of choice for chemotherapy in cancer treatment. It lies in the group of hydrophobic diterpenoids, which belong to a class of compounds called taxanes (Wani et al., 1971). It is derived from a plant named *Taxus brevifolia*, commonly known as “Pacific Yew” (Weaver 2014), which is an evergreen dioecious tree. Its bark, whose extract was used to isolate taxol, is dark reddish, groovy and grows 4-6 mm thick upon maturity. The variable size of its trees and the intermittent occurrence makes its wood of no commercial value. Many early tribes used the tree for making weapons, and treating injuries, wounds and pain (Taylor 1981).

Discovery of Taxol

It was an initiative by Dr. Jonathan L. Hartwell of the National Cancer Institute (NCI), with collaboration from the United States Department of Agriculture (USDA), in 1960 to screen as many plants as they could in search for antitumor agents. In their efforts to find novel antitumor agents, 15,000 plants and 115,000 extracts were screened. In 1962, Arthur S. Barclay, a botanist from the USDA, collected 650 plant samples with the help of three field assistants (Persinos 1990), that included *T. brevifolia*. The samples of *T. brevifolia* were tested for their cytotoxic activities by NCI researchers. It was then handed over to the Monroe Wall of the Research Triangle Institute (RTI) who, in 1964, along with Mansukh Wani, started working on the isolation of the active component in the *T. brevifolia* extract (Walsh and Goodman 2002). After three years of struggle, the active component of *T. brevifolia* was isolated in 1967 and named Taxol due to the evidence of hydroxyl groups in it (Wall and Wani 1995).

The isolation of taxol then raised another important question of its structure. It was a very difficult task at that time and techniques like mass spectrometry, hydrogen nuclear magnetic resonance ($^1\text{H-NMR}$) and X-ray analysis were applied. After a great deal of hard work, the structure of Taxol (Figure 1) was published in 1971 by Wani and coworkers (Wani *et al.*, 1971). After the publication of Taxol's structure, it was quite clear that it was a unique compound with regards to its structure and properties.

Taxol falls in the class of anticancer drugs that target microtubules. Unlike any other anti-microtubule drug, it has a unique mechanism of action (Figure 2). In studies carried out by Fuchs and Johnson (Fuchs and Johnson 1978), it was indicated that taxol was an inhibitor of cell proliferation by blocking mitosis and arresting the cell in the

G2 and M phase of cell cycle. A more detailed explanation of the mechanism of action of taxol was presented in 1979 by Schiff and coworkers (McGuire *et al.*, 1989), which explained its uniqueness in stabilizing the microtubules to cause cell cycle arrest. Furthermore, it was observed that instead of inhibiting the formation of microtubules, taxol binds to the protein tubulin that promotes the formation of microtubules (Wall and Wani 1995; Schiff *et al.*, 1979 and Parness and Horwitz 1981). The microtubules thus produced are nonfunctional but highly stable. They hinder the spindle formation and cause failure in the cell to divide with an equal number of chromosomes. This activates apoptosis and results in cell death (Rowinsky and Donehower 1995). The discovery of its mechanism along with its unique structure and properties made it a very important candidate for anticancer studies.




Figure 1: Structure of Taxol (Paclitaxel) (taken and modified from Rowinsky and Donehower 1995).

Before taxol could be exploited at a commercial level, development of a better understanding of biosynthetic pathways of




Figure 2: Mechanism of action of Taxol (Weaver, 2014).

taxol in plants was essential. This field grabbed the attention of researchers in the last decade of 20th century where they utilized various techniques, e.g., isotope labelled feeding precursors, cell free enzymology, cDNA library construction and pathway gene cloning techniques, to better understand the biosynthesis in plants. On the basis of feeding experiments, it was suggested that the carbon skeleton of taxol could be produced either by mevalonic acid pathway (MVA) (Zamir *et al.* 1992), or by 2-C-methyl-D-erythritol-4-phosphate (MEP) pathway (Eisenreich *et al.* 1996). Recently, geranylgeranyl pyrophosphate (GGPP) was also suggested as

a precursor of the taxane skeleton (Koepp *et al.*, 1995), which was supported by another study of Hefner and colleagues (1996) where the feeding of *T. brevifolia* stem discs with cyclized di-terpenes resulted in production of radioactive 10-deacetyl baccatin III (intermediate product for taxol biosynthesis) and taxol. On a molecular basis, it has been noted that eight cytochrome p450-mediated, three CoA-dependent acyl/aryl transferases-mediated and some simultaneous steps are involved in the formation of baccatin III. Moreover, the addition of side chain of C-13 is accomplished in 5 more steps (Figure 3) (Croteau *et al.* 2006).




Figure 3: Simplified biosynthetic pathway of Taxol Mechanism of action of Taxol (Taken and modified from Croteau et al. 2006). The abbreviations are: IPP, isopentenyl diphosphate; DMAPP, dimethylallyl diphosphate; IPPI, isopentenyl diphosphate isomerase; GGPP, geranylgeranyl diphosphate; GGPPS, geranylgeranyl diphosphate synthase; OPP denotes the diphosphate moiety.

From Taxol to Paclitaxel

Although taxol (Paclitaxel) is a very important drug in cancer therapeutics, it took more than three decades for taxol to achieve the status of Paclitaxel. The drug entered its phase I trials almost 20 years after its discovery and was approved by the FDA five years after that.

Clinical Trials

Taxol entered its phase I clinical trials in 1984 (Figure 4) and only a year later it was going through phase II trials (Figure 4), but a lack of plant material contributed to taxol once again being delayed during the progress of creating this drug (Walsh and Goodman 2002). It was in 1988 when a complete successful trial of taxol on ovarian cancer was reported by William McGuire of the John Hopkins Oncology Center (McGuire *et al.* 1989). In 1989, when obtaining large quantities of taxol became almost impossible, it was evident that the ‘ownership’ of taxol was about to change and in 1991, NCI selected Bristol-Myers Squibb (BMS), a pharmaceutical company, for the commercialization of taxol (Weaver 2014).

A lot has happened since then. In 1992, BMS trade marked the name Taxol and assigned a new name “Paclitaxel”. It made great progress in getting approval of Taxol for ovarian cancer from The Food and Drug Administration (FDA). Moreover, the Pacific Yew Act was passed that was to ensure the survival of *T. brevifolia*, and thus, would cause no hindrance to the supply of Taxol. Now that Paclitaxel had gained approval, its demand increased even more and forced its manufacturers and suppliers to find an alternative way of synthesizing it. It was mainly because of the shortage of the tree *T. brevifolia* that the suppliers could not meet the demands for this drug. Thus, in 1993, BMS announced its plan to abandon *T. brevifolia* for preparation of taxol and to adopt a semi-synthetic process to make taxol

through 10-DAB. It was approved by the FDA in 1994, along with approval of its use in breast cancer treatment, and thus, after a year, the Pacific Yew Act was also ended. The clinical trials kept on going and due to its efficiency in remitting non-small cell lung cancer (NSCLC), the FDA approved Taxol for its treatment in 1999.

The studies on Paclitaxel are still ongoing and researchers are trying to make it even more efficient. Recent studies show the efficacy of nanoparticle bound paclitaxel (Sparreboom *et al.*, 2005; Jia *et al.*, 2015 and Esfandyari-Manesh *et al.*, 2015). Some studies are focused on finding a way to decrease paclitaxel associated adverse effects, such as the use of adjuvants for targeted drug delivery. One such study involves the use of a lectin, Maackia amurensis agglutinin (MAA), as an adjuvant and shows its efficacy in different cancers (Lalli *et al.*, 2015). Other studies show combinations of different drugs with paclitaxel to enhance its efficacy, like dasatinib (Xiao *et al.*, 2015) and carboplatin (Avelino *et al.*, 2015).

REFERENCES

- Anticancer Drugs. 1998 Aug;9(7):611-9. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. Socinski MA1, Mudd PN Jr, Radomski KM, Steagall A, Lawrence P, Bernard S, Letrent SP, Gonzalez P, Brouwer KL.
- Avelino CU, Cardoso RM, de Aguiar SS, da Silva MJ. 2015. Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel. *J Bras Pneumol.* 41(2):133-42.
- Brown T, Tangen C, Fleming T, Macdonald J. A phase II trial of taxol and granulocyte colony stimulating




Figure 4: Summary of Phase I and Phase II clinical trials of Taxol.

- factor (G-CSF) in patients with adenocarcinoma of the pancreas. *Proc Am Soc Clin Oncol* 1993;13:200
- Cancer J Sci Am. 1998 Jul-Aug;4(4):269-74. Phase II study of Taxol in patients with advanced gastric carcinoma. Ajani JA1, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF.
- Cancer Treat Rep. 1987 Dec;71(12):1171-7. Phase I trial of taxol in patients with advanced cancer. Donehower RC1, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS.
- Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. *J Natl Cancer Inst* 1993;85:388-94.
- Chauviere, G., Guénard, D., Picot, F., Senilh, V., and Potier, P., 1981. Analyse structurale et etude biochimique de produits isolés de l'If: *Taxus baccata* L. (Taxacees).
- Croteau, R*, Raymond E. B. Ketchum, Robert M. Long, Rüdiger Kaspera, and Mark R.
- Denis JN, Greene AE, Guenard D, Voegelien FG, Mangatal L, Potier P. 1988. Highly efficient, practical approach to natural taxol. *J. Am. Chem. Soc.* 110 (17), pp 5917–5919
- Denis JN, Greene AE, Serra AA, Luche MJ. 1986. An efficient, enantioselective synthesis of the taxol side chain. *J. Org. Chem.* 51 (1), pp 46–50
- Dennis R.A. Mans. 2013 From forest to pharmacy: Plant-based traditional medicines as sources for novel therapeutic compounds. *Academia Journal of Medicinal Plants* 1(6): 101-110
- Einzig AI, Gorowski E, Sasloff J, Wiernik PH. Phase II trial of taxol in patients with metastatic renal cell carcinoma. *Cancer Invest* 1991;9:133-6.
- Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. *Invest New Drugs* 1991;9:54-64.
- Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with taxol for advance ovarian adenocarcinoma. *J Clin Oncol* 1992;10:1748-53.
- Eisenreich W, Menhard B, Hylands PJ, Zenk MH, Bacher A (1996) Studies on the biosynthesis of taxol: the taxane carbon skeleton is not of mevalonoid origin. *Proc Natl Acad Sci U S A.* 93:6431-6436.
- Esfandyari-Manesh M, Mostafavi SH3, Majidi R, Koopaei MN, Ravari NS, Amini M, Darvishi B, Ostad SN, Atyabi F, Dinarvand R. 2015. Improved anticancer delivery of paclitaxel by albumin surface modification of PLGA nanoparticles. *Daru.* 23(1): 28.
- Ettinger DS, Finkelstein DM, Sarma R, Johnson DH. Phase II study of taxol in patients with extensive-stage small cell lung cancer. *Proc Am Soc Clin Oncol* 1993;12:329.
- Fabricant DS, Farnsworth NR (2001). The value of plants used in traditional medicine for drug discovery. *Environ. Health Perspect.* 109(suppl 1):69–75.
- Firm RD, Jones CG (2003). Natural products - a simple model to explain chemical

- diversity. *Nat. Prod. Rep.* 20:382-391.
- Forastiere AA, Neuberg D, Taylor SG, Deconti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group trial. *Monogr Natl Cancer Inst* 1993;15:181-4.
- Fuchs DA, Johnson RK. 1978. Cytologic evidence that taxol, an antineoplastic agent from *Taxus brevifolia*, acts as a mitotic spindle poison. *Cancer Treat. Rep.* 62: 1219-1222
- Gershezon J, Kreis W (1999) Biochemistry of terpenoids. In: Wink, M. (ed). *Biochemistry of plant secondary metabolism.* Sheffield Academic Press, London (UK) pp.222–279.
- Hefner J, Rubenstein SM, Ketchum REB, Gibson DM, Williams RM, Croteau R (1996) Cytochrome P450-catalyzed hydroxylation of taxa-4(5),11(12)-diene to taxa-4(20),11(12)-dien-5 α -ol: the first oxygenation step in taxol biosynthesis. *Chem Biol.* 3:479-489.
- Holmes FA, Valero V, Theriault RL, et al. Phase II trial of taxol (T) in metastatic breast cancer (MBC) refractory to multiple prior treatments. *Proc Am Soc Clin Oncol* 1993;12:94.
- Hurwitz CA, Relling MV, Weitman SD, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study. *J Clin Oncol* 1993;11:2324-9.
- Invest New Drugs. 1991 Feb;9(1):59-64. A phase II study of taxol in patients with malignant melanoma. Einzig AI, Hochster H, Wiernik PH, Trump DL, Dutcher JP, Garowski E, Sasloff J, Smith TJ.
- J Clin Oncol.* 1991 Sep;9(9):1692-703. Sequences of taxol and cisplatin: a phase I and pharmacologic study. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, et al.
- J Clin Oncol.* 1994 Feb;12(2):241-8. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D.
- J Clin Oncol.* 1997 Apr;15(4):1409-17. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study. Frasci GI, Comella P, Scoppa G, Guida C, Gravina A, Fiore F, Casaretti R, Daponte A, Parziale A, Comella G.
- Jia L, Li Z, Shen J, Zheng D, Tian X, Guo H, Chang P. 2015. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance. *Int J Pharm.* pii: S0378-5173(15)00420-2.
- Kirschling RJ, Jung SH, Jett JR. A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer. *Proc Am Soc Clin Oncol* 1994;13:326.
- Koepp AE, Hezari M, Zajicek J, Vogel BS, LaFever RE, Lewis NG, Croteau R (1995) Cyclization of geranylgeranyl diphosphate to taxa-4(5),11(12)-diene is the committed step of taxol biosynthesis in Pacific yew. *J Biol Chem.* 270:8686-8690.
- Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant

- recurrent ovarian cancer. *J Natl Cancer Inst* 1994;86:18-24.
- Lalli RC, Kaur K, Dadsena S, Chakraborti A, Srinivasan R, Ghosh S. 2015. *Maackia amurensis* agglutinin enhances paclitaxel induced cytotoxicity in cultured non-small cell lung cancer cells. *Biochimie. pii: S0300-9084(15) 00136-4*.
- Laskin MS, Lucchesi KJ, Morgan M. Paclitaxel rechallenge failure after a major hypersensitivity reaction. *J Clin Oncol* 1993;11:2456-7.
- Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. *Cancer* 1990;65:2478-81.
- Manfredi JJ, Parness J, Horwitz SB. 1982. Taxol Binds to Cellular Microtubules. *J. Cell Biol.* 94: 688-696
- McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. 1989. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. *Ann. Intern. Med.* 111: 273-279
- Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. *J Clin Oncol* 1994;12:2277-83.
- Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated non-small-cell lung cancer. *J Natl Cancer Inst* 1993;85:384-8.
- Ohnuma T, Zimet AS, Coffey VA, Holland JF, Greenspan EM. Phase I study of taxol in a 24-hour infusion schedule. *Proc Am Assoc Cancer Res* 1985;26:167.
- Oncology. 1997 Mar-Apr;54(2):89-95. Paclitaxel administered over 3 h followed by cisplatin in patients with advanced head and neck squamous cell carcinoma: a clinical phase I study. Schilling T1, Heinrich B, Kau R, Herzog M, Quasthoff S, Diergarten K, Rastetter J, Hanauske AR.
- Parness J, Horwitz SB. 1981. Taxol binds to polymerized tubulin in vitro. *J Cell Biol.* 91: 479-87.
- Persinos, E. (ed.). *Washington Insight*, September 15, 1990
- Rhoades DF (1979). Evolution of plant chemical defense against herbivores. In: Rosenthal GA and Janzen DH (eds): *Herbivores, their interaction with secondary plant metabolites*. Academic Press, Boston (USA). pp. 1-55
- Roth BJ, Dreicer R, Einhorn LH, et al. Paclitaxel in previously untreated, advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group (ECOG). *Proc Am Soc Clin Oncol* 1994;13:230.
- Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. *Cancer* 1993;72:2457-60.
- Rowinsky EK, Donehower RC. 1995. Paclitaxel (taxol). *N Engl J Med.* 332(15): 1004-14
- Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. *J Clin Oncol* 1992;10:1165-70.

- Schiff PB, and Horwitz SB. 1980. Taxol stabilizes microtubules in mouse fibroblast cells. *Proc. Natl. Acad. Sci. USA.* 77(3): 1561-1565
- Schiff PB, Fant J, Horwitz SB. 1979. Promotion of microtubule assembly in vitro by taxol. *Nature.* 277: 665-7.
- Semin Oncol. 1995 Dec;22(6 Suppl 14):19-22. Paclitaxel and simultaneous radiation in the treatment of stage III A/B non-small cell lung cancer. Havemann K1, Wolf M, Goerg C, Faoro C, Pfab R, Diergarten K.
- Semin Oncol. 1995 Dec;22(6 Suppl 15):29-33. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results. Belli L1, LeChevalier T, Gottfried M, Adams D, Ruffie P, LeCesne A, Tete L, Pellae-Cosset B.
- Semin Oncol. 1995 Dec;22(6 Suppl 15):50-4. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R1, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
- Semin Oncol. 1996 Dec;23(6 Suppl 16):120-3. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study. Vogt HG1, Kolotas C, Martin T, Schneider LV, Goes-Schmieder R, Mitrou PS, Diergarten K, Kober B, Zamboglou N.
- Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. 2005. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). *Clin Cancer Res.* 11(11): 4136-4143
- Taylor, R. L. and S. Taylor. 1981. *Taxus brevifolia* in British Columbia. *Davidsonia* 12(4): 89--94.
- Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecological Oncology Group study. *J Clin Oncol* 1994;12:1748-53.
- Tuma RS. 2003. Taxol's journey from discovery to use: lessons and updates. *Oncol Times* 25, 52–57.
- Wall ME, Wani MC. 1995. Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. *Cancer Res.* 55(4): 753-60.
- Walsh V, Goodman J. 2002. From taxol to Taxol: the changing identities and ownership of an anti-cancer drug. *Med Anthropol* 21, 307–336.
- Wani MC, Taylor HL, Wall ME, Coggan P, McPhail AT. 1971. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc.* 93: 2325-7.
- Weaver BA. 2014. How Taxol/paclitaxel kills cancer cells. *Mol Biol Cell.* 25(18): 2677-81.
- Wildung. Taxol biosynthesis and molecular genetics. *Phytochem Rev.* 2006 February ; 5(1): 75–97. doi:10.1007/s11101-005-3748-2.
- Williams, D. H., Stone, M. I., Hauck, P. R., and Rahman, S. K. 1989 Why are secondary metabolites (natural

J. Bioresource Manage. (2015) 2(4): 28-39.

products) biosynthesized? *J. Nat. Prod.* (Lloydia), 52: 1189-1208.

Wilson WH, Berg S, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. *J Clin Oncol* 1994;12:1621-9.

Wilson WH, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. *J Clin Oncol* 1995;13:381-6.

Wink M (2003). Evolution of secondary metabolites from an ecological and molecular phylogenetic perspective. *Phytochemistry*, 64:3-19.

Xiao J, Xu M, Hou T, Huang Y, Yang C, Li J. 2015. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling. *Mol Med Rep.* doi: 10.3892/mmr.2015.3784.

Zamir LO, Nedeau ME, Garneau FX (1992) Biosynthetic building blocks of *Taxus canadensis* taxanes. *Tetrahedron Lett.* 33:5235-5236.
